From Big Pharma to Conservation Chemistry: The New Frontier in Drug Design

Tim Cernak spent nearly 20 years in Big Pharma, developing precision therapies for major diseases. But by 2018, he was ready for a new challenge: using his expertise to treat animals, not humans. This shift signals a potential revolution in how we think about pharmaceuticals and conservation.

Chronology

Cernak's journey began in 2018, when he decided to put his skills to a new use. For nearly two decades, he worked with pharmaceutical giant Merck crafting therapies for cancer, HIV, and diabetes. These human-targeted drugs aimed to zero in on diseased cells while sparing healthy ones. But a growing concern for the environment led him to explore how his skills could help wildlife.

Animals often receive drugs designed for humans, which can be harmful. For instance, the antifungal itraconazole, used to treat frogs with skin infections, is often lethal. Cernak wanted to change this, imagining a world where the drugs were initially meant for the frogs themselves. By 2023, he was working at the University of Michigan, treating various creatures from Gila monsters to bald eagles, with a focus on conservation chemistry.

Impact

Cernak's shift has brought significant changes. Using AI, specifically Google DeepMind’s AlphaFold model, he can visualize proteins in 3D, dramatically speeding up drug design. Traditional methods are slow and expensive, but AI allows him to test up to 1,500 drug reactions daily using lab robots. This acceleration in drug development could transform conservation efforts, making them faster and more effective.

The impact is widespread. Loggerhead sea turtles, which suffer from contagious tumors, are one of his many patients. Cernak feels a connection to creatures that benefit humans, like the Gila monster, whose hormones contributed to weight-loss drugs like Ozempic. He's also working on precision insecticides to save hemlock trees from invasive species.

Here's the thing. By applying advanced technology to conservation, Cernak is stepping into a field where chemistry hasn't always been welcome. Historically, chemicals like DDT have harmed wildlife, but Cernak believes excluding chemists from conservation is a missed opportunity.

Outlook

So, what does this mean for the future of pharmaceuticals and conservation? Cernak's work highlights a potential new market for drug design that's both profitable and ethical. The possibilities are vast. Imagine pharmaceutical advancements focused not just on curing human diseases, but also on preserving biodiversity. The reality is, the line between medicine for humans and animals is blurring, offering new avenues for growth.

From a risk perspective, this approach involves challenges. Balancing efficacy with environmental safety is tricky. But the numbers tell the story. With the global AI drug discovery market estimated to reach $4.8 billion by 2027, there's immense potential in expanding these technologies into conservation.

In the end, who wins and who loses from this shift? Pharmaceutical companies entering conservation chemistry could find new revenue streams. Wildlife and ecosystems could gain from more targeted and less harmful treatments. But those resistant to change might fall behind. As we move forward, Cernak's pioneering work serves as a reminder that the boundaries of drug design are only as limited as our imaginations.